Launched in 2001, VICTOR randomised patients with
stage II or III colon and rectal cancer that had completed
standard adjuvant therapy to 2 years of rofecoxib,
5 years of rofecoxib or placebo, before it was prematurely
suspended in 2005 when rofecoxib was withdrawn
from the market